New therapeutical horizons in the management of postmenopausal osteoporosis.
Osteoporosis is a bone metabolic disease characterized by a compromised skeletal fragility, leading to an increased risk of developing spontaneous and traumatic fractures. This disease is the consequence of an imbalance of the physiological process of bone turnover (or coupling), with the lost of the equilibrium between the activity of osteoblasts and osteoclasts. Therapy has been aimed mainly at the correction of the imbalance between bone resorption and bone formation, to protect skeletal integrity and reduce the risk of fractures. Thus, pharmacological treatments have been aimed at modulating the activity of bone cells.
Endocrinology Unit, Department of Movement, Human and Health Sciences, University of "Foro Italico", Largo de Bosis 14, 00135, Rome, Italy, migliacciosilvia@hotmail.it.
Silvia
S
Migliaccio
Rachele
R
Fornari
Emanuela A
EA
Greco
Luigi
L
Di Luigi
Andrea
A
Lenzi
D048868:Adaptor Proteins, Signal Transducing; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use; D016723:Bone Remodeling; D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology*; D056657:Cathepsin K / Q000627:therapeutic use; D000069448:Denosumab; D005260:Female; D005819:Genetic Markers; D006801:Humans; D010006:Osteoblasts / Q000166:cytology*; D010010:Osteoclasts / Q000166:cytology*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012306:Risk; D019379:Teriparatide / Q000627:therapeutic use
D048868:Adaptor Proteins, Signal Transducing; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; D019379:Teriparatide; D000069448:Denosumab; D056657:Cathepsin K